Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 10000
- Registration Number
- NCT06953726
- Locations
- 🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
Apixaban in Thrombocytopenia
- Conditions
- Deep Vein ThrombosisPulmonary Embolism and ThrombosisThrombocytopeniaRecurrent Venous Thromboembolism
- Interventions
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Rushad Patell
- Target Recruit Count
- 30
- Registration Number
- NCT06886516
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
- Conditions
- Acute Myocardial Infarction of Anterior WallLeft Ventricular ThrombusProphylaxis
- Interventions
- Drug: Control (Standard treatment)
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 472
- Registration Number
- NCT06742567
- Locations
- 🇵🇰
NICVD Pakistan, Karachi, Sindh, Pakistan
A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation
- Conditions
- AnticoagulantsVenous Malformation, Low Flow
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06729034
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
- Conditions
- Staphylococcus Aureus EndocarditisStaphylococcus Aureus SepticemiaStaphylococcus Aureus BacteremiaStaphylococcus Aureus Bloodstream InfectionS. Aureus BacteremiaS. Aureus Bloodstream Infection
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Emily McDonald
- Target Recruit Count
- 300
- Registration Number
- NCT06650501
- Locations
- 🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
- Conditions
- End-Stage Kidney Disease (ESKD)Non-valvular Atrial Fibrillation (NVAF)Venous Thromboembolism (VTE)
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Abu Dhabi Health Services Company
- Target Recruit Count
- 67
- Registration Number
- NCT06606275
- Locations
- 🇦🇪
SEHA Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
- Conditions
- Venous ThromboembolismCancerUpper Extremity Deep Vein ThrombosisCatheter-Related Infections
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 330
- Registration Number
- NCT06603870
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
Dabigatran Versus Apixaban in Cerebral Venous Thrombosis
- Conditions
- Cerebral Venous Sinus Thrombosis
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 200
- Registration Number
- NCT06551415
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
- Conditions
- Cerebral Venous Thrombosis
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 200
- Registration Number
- NCT06531122
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Clinical Urology and Epidemiology Working Group
- Target Recruit Count
- 5436
- Registration Number
- NCT06523959
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.